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Abstract: B-cells play an important role in the diagnosis and to some extent the pathogenesis 
of many autoimmune diseases. Speciﬁ  c B-cell directed antibodies are now gaining an increasing 
role in the management of these diseases. The ﬁ  rst antibody target in this regard was CD20, with 
the development and introduction of rituximab in the management of B-cell malignancies as well 
as rheumatoid arthritis. A second candidate target is CD22, and the ﬁ  rst antagonistic antibody 
to this B-cell marker is epratuzumab, which appears to function, in contrast to CD20 antibod-
ies, more by modulation of B-cells than by their depletion capacity. Originally developed for 
the treatment of non-Hodgkin lymphoma, epratuzumab has now been reported to be effective, 
with a very good safety proﬁ  le, in two prototype autoimmune diseases, systemic lupus ery-
thematosus and primary Sjögren’s syndrome. As such, this new investigational antibody may 
provide distinct therapeutic effects and may be complementary to the known effects and role 
of CD20 antibodies.
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Autoimmune diseases
Autoimmune diseases comprise more than 80 chronic diseases that affect about 5%–8% 
of the general population (Jacobson et al 1997), with the prevalence being, in decreasing 
order, rheumatoid arthritis (RA), primary Sjögren’s syndrome (pSS), and systemic 
lupus erythematosus (SLE). There has been considerable progress made in understand-
ing the immune system during recent decades, resulting in a better appreciation of the 
role of B-cells in the interaction of innate and adaptive immunity, lymphocyte activation 
and antigen processing, the principles of immune tolerance, B- and T-cell crosstalk, 
cytokine signaling, and new approaches of treating autoimmune diseases by depleting 
or modulating B-cells, including blockade of co-stimulation. This resulted in a plethora 
of articles and reviews on the importance of B-cells in autoimmunity (Mitchison and 
Wedderburn 2000; Edwards and Cambridge 2001; Lipsky 2001; De Vita et al 2002; 
Leandro et al 2002a; Dörner and Burmester 2003; Oligino and Dalrymple 2003; Uchida 
et al 2004; Park et al 2005; Tedder et al 2005a; Keystone 2005; Viau and Zouali 2005; 
Dörner 2006; Dörner and Lipsky 2006; Martin and Chan 2006).
These diseases, particularly RA, SLE, and pSS, are complex, usually multi-organ 
manifestations with a wide heterogeneity in clinical presentations and disease course. 
Whereas many were traditionally considered to implicate T-cells in their pathogenesis, as 
referenced above, B-cell disturbances and hyperactivity are now considered to be a hall-
mark of many of these diseases, as indicated by the development of autoantibodies, and 
an increased risk of developing B-cell lymphoma, such as in pSS and RA (Voulgarelis 
et al 1999). Although B-cells were attributed previously only to cause autoantibody pro-
duction, they have now gained a central role in the pathogenesis of several autoimmune 
diseases. A breakdown of tolerance mechanisms that normally regulate B-cell develop-
ment leads to the development of autoimmune diseases (William et al 2006), including Therapeutics and Clinical Risk Management 2007:3(5) 954
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induction and maintenance of self-reactive B-cell antigen 
receptor (BCR) complexes (Voulgarelis Dafni et al 1999; 
Dörner 2006; Dörner and Lipsky 2006; Martin and Chan 
2006; Radbruch et al 2006). Because B-cells are considered 
as being of central importance in the immunopathogenicity, 
they represent current targets of immunotherapy.
To date, there are a number of therapeutic antibodies 
targeting B-cell-speciﬁ  c antigens in order to deplete or 
modulate B-cells, rituximab (anti-CD20 chimeric antibody), 
ocrelizumab (humanized anti-CD20 antibody), belimumab 
(anti-BlyS or BAFF human antibody), and epratuzumab 
(anti-CD22 humanized antibody) that are in advanced clinical 
trials in several autoimmune diseases (Dörner 2006; Dörner 
and Lipsky 2006; Edwards and Cambridge 2006; Martin 
and Chan 2006). A number of other anti-CD20 antibodies 
(HuMax, hA20 or veltuzumab, ofatumumab) are also in 
clinical development but no clinical data have been reported 
so far other than in abstract form.
Rituximab was the ﬁ  rst monoclonal antibody approved 
by the US Food and Drug Administration for the treatment of 
B-cell non-Hodgkin’s lymphoma (NHL) in 1997, followed 
by licensing for RA after anti-TNF failure in 2006. The suc-
cess and the very good safety proﬁ  le of rituximab therapy in 
lymphoma, as well as incidental case observations, encouraged 
many investigators to consider its use in autoimmune diseases. 
In the last 4-years, clinical trials have shown promising efﬁ  cacy 
in various autoimmune diseases (Edwards and Cambridge 
2006), such as RA (Edwards et al 2004b; Leandro et al 2002a), 
Sjögren’s syndrome (Pijpe et al 2005), SLE (Leandro et al 
2002b), and chronic immune thrombocytopenic purpura (Stasi 
et al 2001). These studies indicated that circulating B-cells are 
undetectable after a brief dosing regimen of rituximab. Whether 
complete depletion of peripheral B-cells and remaining 
CD20- plasmablasts may be used as a biomarker of clinical 
response needs further careful analysis in RA. Long-term 
efﬁ  cacy and safety was reported in RA (Edwards et al 2004a), 
which is the ﬁ  rst autoimmune disease indication approved 
recently for rituximab in combination with methotrexate 
and corticosteroids. Fully human and humanized anti-CD20 
monoclonal antibodies are now under further evaluation in 
autoimmune diseases (Stein et al 2004; Teeling et al 2004; 
Tahir et al 2005) with ocrelizumab being in advanced trials. 
Nevertheless, all of these CD20 antibodies appear to markedly 
deplete circulating B-cells in treated patients. Depleting B-cells 
is a new and interesting method in the treatment of autoimmune 
diseases, although there are still too limited long-term safety 
data, and reduced Ig levels indeed were reported in a 7-year 
experience in RA (Edwards and Cambridge 2006).
A distinct and novel approach is to modulate B-cell 
function, perhaps targeting a speciﬁ  c B-cell population or 
functional target. B-cell survival and selection is determined 
by BCR speciﬁ  city, and downstream signaling is affected by 
the interaction of numerous enzyme cascades, other critical 
receptors, and target molecules (Dörner and Lipsky 2006). 
Recently, the CD22 molecule indigenous to B-cells has 
gained considerable attention as an important co-receptor in 
BCR function and in autoimmunity, and thus as a potential 
target for autoimmune therapy (Nitschke 2005; Tedder et al 
2005a; Goldenberg 2006).
Current concepts for treating 
systemic lupus erythematosus
An important consideration in the treatment of SLE is that this 
heterogeneous disease may have very different organ manifes-
tations, suggesting that the treatment should be determined by 
the extent of the involvement of major organ systems, so that 
disease activity determines treatment options. However, with 
the exception of studies in lupus nephritis, trials evaluating 
the functional outcome of other organs are limited.
Severe internal organ involvement usually requires 
immunosuppression. In lupus nephritis, it has been shown 
that mycophenolate mofetil in combination with corticoste-
roids (Chan et al 2000; Contreras et al 2004) are sufﬁ  cient 
for initial therapy. Rapidly progressive lupus nephritis has 
been shown to be controlled by iv cyclophosphamide monthly 
for 6 months (Boumpas et al 1992), and subsequently 
followed by azathioprine, mycophenolate mofetil or conti-
nous iv cyclophosphamide every 3 months. ACE and AT1 
inhibitors can reduce proteinuria and retard renal sclerosis in 
membranous nephritis. Involvement of the central nervous 
system with encephalopathy and transverse myelitis usually 
requires high doses of corticosteroids, often combined with 
cyclophosphamide. Since lupus and also high doses of cor-
ticosteroids can induce psychosis, these clinical situations 
are challenging.
Most of the treatment strategies have been developed 
or signiﬁ  cantly modiﬁ  ed within the last decade, espe-
cially the use of iv cyclophosphamide and introduction 
of mycophenolate mofetil for improving the outcome of 
severe lupus. However, the side effects of non-speciﬁ  cally-
acting drugs, as well as the combination with high dose 
corticosteroids, are serious (ovarian failure, enhanced 
risk for bladder carcinoma, enhanced infection rate, 
infusion-related side effects; ie, nausea, vomiting, hair 
loss). Although cyclophosphamide and corticosteroids have 
effects on B-cells, the advent of B-cell directed therapies Therapeutics and Clinical Risk Management 2007:3(5) 955
CD22 as a strategy for treating systemic autoimmune diseases
using speciﬁ  c antibodies against CD20, CD22, and against 
B-cell survival factors and cytokines (anti-BAFF, anti-BR3, 
TACI-Ig, anti-IL10, anti-IL6), or agents modulating B-cell 
receptor strength (LJP394, Epratide) provide different 
mechanisms of action, potential different efﬁ  cacies and 
different adverse events. Currently available data indicate 
that the side effects of anti-CD20 and anti-CD22 antibody 
therapies are acceptable, although long-term data are still 
not available.
Beyond B-cell directed biotherapies, there are numerous 
new strategies under study, such as peptide vaccinations, 
neutralizing complement 5, FcγRIIB, PDGF blockade by 
Gleevec, inducing regulatory T-cells, blocking ligand inter-
actions (ie, ICOS/ICOS-L, CD40/CD40L and CD80/86 
blockades), autologous stem cell transplantation, and high-
dose cyclophosphamide.
CD22 molecule
CD22 is a 135-kD type I transmembrane sialoglycoprotein 
of the immunoglobulin (Ig) superfamily that is the focus of 
two recent comprehensive reviews (Nitschke 2005; Tedder 
et al 2005b). The expression of CD22 is speciﬁ  c to B-cells 
and is developmentally regulated so that it is expressed at 
low levels in the cytoplasm of pro-B and pre-B-cells, and its 
localization shifts to the cell surface and higher expression 
on mature IgM+, IgD+ B-cells (Dörken et al 1986). CD22 is 
strongly expressed on follicular, mantle, and marginal-zone 
B-cells, but is weakly present in germinal B-cells (reviewed 
in (Nitschke 2005; Tedder et al 2005b)).
CD22 consists of 7 extracellular Ig domains and a full-
length 141 amino acid cytoplasmic tail (Wilson et al 1991; 
Engel et al 1995). Human CD22 genes have 15 or more 
exons, where the single Ig domains are encoded by exons 
4–10 and the transmembrane and cytoplasmic domains 
encoded by exons 11–15. Immunoprecipitation studies have 
shown that different monoclonal antibodies to CD22 react 
with different Ig domains. Epratuzumab has been found to 
compete with the RFB4 antibody, which binds to the third 
Ig domain (Stein et al 1993).
Functionally, CD22 is involved in regulating B-cell 
function by CD19 and B-cell antigen receptor (BCR) signal 
transduction, BCR-induced cell death, and the survival of 
B-cells in peripheral organs. Because CD22 is considered to 
be a regulator of B-cell functions and survival, it appears to 
be an important link for modulating humoral immunity and 
also the proliferation of B-cell lymphomas. Therefore, CD22 
is a candidate target for therapeutic antibodies (Tedder et al 
2005b; Goldenberg 2006; Steinfeld and Youinou 2006).
In vitro assays indicate that CD22 plays a role in inter-
cellular adhesion, involving α2-6-linked sialic acid residues 
(Stamenkovic and Seed 1990; Engel et al 1993). CD22 
is thus considered to be a member of the sialoadhesin or 
SigLec subclass of the Ig superfamily, characterized by 
functioning as lectins (Engel et al 1993; Kelm et al 1994), 
whose members include other sialic acid-binding receptors, 
such as sialoadhesin and CD33. CD22 adhesion has been 
implicated in a variety of functions, such as interacting with 
neighboring leukocytes, regulator of signaling, such as gen-
erating either costimulatory, resulting in cell proliferation, or 
apoptotic signals on B-cell function after being treated with 
CD22 antibodies (Chaouchi et al 1995; Doody et al 1995; 
Tuscano et al 1999). In an in vitro assay system, immobi-
lized epratuzumab crosslinked with anti-IgG had different 
effects, depending on the cell type studied. In the situation 
of B-cell lymphomas expressing CD22, epratuzumab, when 
immobilized, inhibited cell proliferation, but did not do so 
when not immobilized, even when crosslinked (Carnahan 
et al 2003, 2007). CD22 has been reported to be a nega-
tive regulator of signaling (Otipoby et al 1996; Sato et al 
1996; Nitschke et al 1997; O’Keefe et al 1999). However, 
our own studies with human B-lymphoma cells suggest an 
involvement of CD22 with the BCR, where it can inhibit 
proliferative functions (Carnahan et al 2007) that may be 
operative in epratuzumab’s activity against NHL and certain 
autoimmune diseases. Blocking CD22 in vivo in different 
settings and involving different B-cell populations needs to 
be studied further in order to further elucidate the complex 
role of CD22 and various antagonistic antibodies in B-cell 
development and in B-cell diseases.
Epratuzumab
Epratuzumab was derived from the murine IgG2a mono-
clonal antibody, LL2 (originally named EPB-2) generated 
against Raji Burkitt lymphoma cells, and found to be highly 
selective for normal B-cells and B-cell tumors, but not reac-
tive with Hodgkin’s disease, solid tumors, or non-lymphoid 
tissues (Pawlak-Byczkowska et al 1989). It was shown to 
bind to the third Ig-like domain of CD22 (Stein, Belisle, 
Hansen, and Goldenberg 1993). The antibody was found to 
rapidly internalize (107 molecules/min) into CD22-positive 
lymphoma cells) (Shih et al 1994), and induces CD22 phos-
phorylation (Carnahan et al 2003).
Epratuzumab (hLL2), the humanized IgG1(κ) form of 
the murine LL2, was further developed for clinical use 
(Leung et al 1994). Its known mechanisms of action differ 
from the anti-CD20 monoclonal antibody which depletes Therapeutics and Clinical Risk Management 2007:3(5) 956
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very efficiently CD20+ B-cells, rituximab, by CD22 
phosphorylation (Carnahan et al 2003) and by affecting BCR 
(via immobilized immunoglobulin crosslinking), as well as 
inducing moderate, but signiﬁ  cant, ADCC, without showing 
direct apoptotic or complement-mediated killing (Carnahan 
et al 2003). Epratuzumab has also been shown depletion of 
circulating B-cells when given to patients with NHL (Leonard 
et al 2002; Leonard et al 2003), SLE (Dörner et al 2006), or 
pSS (Steinfeld et al 2006), but markedly less than rituximab 
(Reff et al 1994), yet has been active therapeutically in all three 
diseases. Epratuzumab at the dose of 360 mg/m2 in 250 mL 
0.9% NaCl is administered i.v. as a slow infusion (less than 
1 hour). In order to minimize hypersensitivity, patients were 
premedicated with acetaminophen and antihistamine.
Chemistry
Epratuzumab is a humanized MAb of IgG1(κ) class, which spe-
ciﬁ  cally binds to the CD22 antigen in B-cells. The construct 
encoding epratuzumab was created by grafting the comple-
mentarity-determining regions (CDR) of the murine parental 
origin antibody in a human IgG1 genetic backbone (Leung 
et al 1994, 1995). The resulting epratuzumab contains the 
original murine sequence only at the antigen-binding sites, 
comprising about 10% of the molecule, the remainder being 
the human framework sequences. The antibody is formulated 
in 0.04 M sodium phosphate–0.15 M sodium chloride, pH 
7.4, buffer with 0.075 % polysorbate 80.
Pharmacokinetics and pharmacodynamics
To date, pharmacokinetic (PK) results are available for 
unlabelled epratuzumab from patients enrolled in Phase I/II 
chemotherapy-refractory NHL, SLE, and pSS studies. Phar-
macokinetic analyses showed that mean maximum antibody 
levels generally increased with increasing epratuzumab dose. 
The mean serum half-life (t1/2) increased from 6.9-days to 
26.5-days between the ﬁ  rst and the fourth infusion (Leonard 
et al 2002, 2003), while the highest serum values (Cmax) 
increases with subsequent doses, findings likely due to 
the saturation of CD22-binding sites. Epratuzumab serum 
levels were still detectable at week 12 post-infusion. Non-
compartmental pharmacokinetic analysis indicated a serum 
half-life (t1/2) after the fourth infusion of 15 ± 8 days in pSS 
patients (Steinfeld et al 2006) and 23-days in NHL patients 
(Leonard et al 2003).
Drug administration and interactions
No drug interaction has yet been reported with epratuzumab. 
In addition, neither an overdose effect of epratuzumab nor an 
antidote to overdose is known. However, due to the potential 
for hypotension, it is recommended for subjects receiving 
daily anti-hypertensive medication that the medication be 
held until after completion of their epratuzumab infusion. 
It is noteworthy that, in contrast to many other antibodies 
in human use, epratuzumab has been infused within 1 hour 
and has shown good tolerance, with usually only grade 1 or 
2 reactions (according to NCI CTC grading).
Epratuzumab in SLE and primary 
Sjögren’s syndrome
Two Phase II open label studies were conducted in patients 
with autoimmune diseases.
The ﬁ  rst study of anti-CD22 in the treatment of 14 patients 
with moderately active SLE was reported using the BILAG 
(British Isles Lupus Assessment Group) scoring method to 
categorize SLE activity levels (Dörner et al 2006). Patients 
received 360 mg/m2 epratuzumab intravenously every 2 weeks 
for 4 doses, with analgesic/antihistamine premedication (but 
no steroids) prior to each dose. Evaluations at 6, 10, 18, and 
32 weeks (6 months post-treatment) follow-up included 
safety, SLE activity (BILAG score), blood levels of epratu-
zumab, B- and T-cells, immunoglobulins, and human anti-
epratuzumab antibody (HAHA) titers. Total BILAG scores 
decreased by 50% in all 14 patients at some point during the 
study (including 77% with 50% decreases at 6 weeks), with 
92% having various levels of decreases continuing to at least 
18 weeks (where 38% showed 50% decreases). Almost 
all patients (93%) experienced improvements in at least one 
B- or C-level disease activity at 6 weeks, and all patients 
achieved improvement in at least one BILAG body system 
at 10 weeks. Complete resolution of all BILAG B-level 
disease activities was seen in three patients at 18 weeks. 
Epratuzumab was tolerated well, with a median infusion 
time of 32 min. Drug serum levels were measurable for at 
least 4 weeks post-treatment and detectable in most samples 
at 18 weeks. B-cell levels decreased by an average of 35% at 
18 weeks and remained depressed at 6 months post-treatment. 
Changes in routine safety laboratories were infrequent and 
without any consistent pattern, and there was no evidence 
of immunogenicity or signiﬁ  cant changes in T-cells, immu-
noglobulins, or autoantibody levels. Of note, the anti-CD22 
antibody preferentially reduced naïve CD27- B-cells and 
has been shown by in vitro studies to inhibit proliferation of 
activated B-cells, especially blocking TLR-dependent activa-
tion by CpG and to a lesser degree by CD40/CD40L (Jacobi 
et al 2007). Further randomized trials in SLE are underway 
to evaluate efﬁ  cacy and safety of epratuzumab in SLE.Therapeutics and Clinical Risk Management 2007:3(5) 957
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Another open-label trial was conducted (Steinfeld et al 
2006) in 15 patients with pSS. In this two-center study, the 
patients were on symptomatic treatment for at least 6 months 
prior to entry and were not on steroids or immunosuppres-
sive drugs (hydroxychloroquine, methotrexate, cyclosporin, 
sulfasalazine, or corticosteroids were not allowed during the 
study and were discontinued at least 4 weeks before study 
entry). They received the same infusions of epratuzumab 
every other week for 4 doses, as in the SLE trial. The patients 
had active pSS based on increased erythrocyte sedimentation 
rates (ESR) and/or serum IgG levels, as well as at least one 
systemic manifestation. A composite endpoint involving 
the objective measures of eyes and mouth dryness, fatigue, 
and two laboratory parameters (ESR and IgG), was used to 
provide a clinical measure of response. Accordingly, a patient 
responded if there was a 20% improvement in at least two 
of these parameters. This study found that 53% of the patients 
achieved a clinically meaningful response 24 hours follow-
ing the fourth infusion, or at 6 weeks. A higher response 
rate (67%) was observed at 32 weeks, or about 6 months 
after completion of therapy, suggesting possible recovery 
or regeneration of the glandular tissues. Circulating CD19+ 
B-cell levels decreased (mean change from baseline ±50%) 
for at least 12 weeks after the last infusion. However, no 
improvement in the antinuclear antibody titers was observed 
from baseline values.
Further trials with epratuzumab in patients with SLE 
are currently being conducted by UCB SA of Brussels, 
which licensed the product from Immunomedics, Inc., for 
autoimmune disease indications.
Safety and tolerability
Epratuzumab has been generally well tolerated in the studies 
cited above. Most reactions were transient, mild-to-moderate 
adverse events that resolved without sequelae, including 
nausea, fatigue, and general pain. The most treatment-related 
events were transient mild-to-moderate (Grade 1–2) infusion 
reactions, occurring mainly during the initial infusion. 
In order to minimize hypersensitivity, patients were pre-
medicated with acetaminophen (0.5–1 g) and antihistamine 
(25–50 mg p.o. or IV benedryl, polaramin, or an equivalent). 
However, patients with pSS appeared to have a higher rate of 
adverse events. One patient experienced a moderate-severe 
acute infusional reaction (ﬂ  ushing, dyspnea, nausea, vomit-
ing, nasal mucosa swelling, and glottis pressure) during 
the ﬁ  rst infusion. 93% of the pSS patients completed all 
infusions. Another patient prematurely terminated the third 
infusion after experiencing a grade-3 acute infusion reaction. 
Adverse events were reported in 10/16 patients, with 4 having 
severe events. Interestingly, pSS patients treated with rituxi-
mab (Pijpe et al 2004) were reported also to have a higher 
rate of side effects, including the development of serum 
sickness. Standard safety laboratories showed no consistent 
pattern of change, and infrequent post-treatment increases in 
NCI-CTC v 3.0 toxicity grades for these laboratories were 
all limited to changes of at most one grade level. No change 
in serum IgG, IgA, or IgM levels was reported in both NHL 
and autoimmune disease studies.
Human anti-human antibody (HAHA) titers were deter-
mined in collected blood samples by Immunomedics, Inc., 
to determine the agent’s immunogenicity. In NHL and 
Sjögren’s syndrome studies, only 2.4% of the patients had 
positive ELISA assay results, all borderline positives or low-
level values, and there were no associated clinical events 
(Steinfeld et al 2006). No evidence of immunogenicity was 
reported in the SLE study (Dörner et al 2006).
Conclusion
More than 300 patients with B-cell NHL received epratu-
zumab either in single-agent or in combination studies with 
rituximab. A small number of approximately 30 patients 
with autoimmune diseases (SLE and Sjögren’s syndrome) 
have received epratuzumab in 2 single-agent Phase II clinical 
trials. Epratuzumab was infused, ususally within an hour, 
with minimal toxicity at the dose of 360 mg/m2 for 4 doses. 
Most treatment-related events were transient mild/moderate 
infusion reactions and preferentially seen in pSS patients. 
There was no evidence of changes in hematology, serum 
chemistry, or immunoglobulins with epratuzumab, except for 
a circulating B-cell drop of up to about 35%–50%, which was 
maintained for several months. Evidence of clinical efﬁ  cacy 
in indolent and aggressive NHL and in both SLE and pSS 
suggests that epratuzumab is a promising new therapeutic 
agent for the treatment of B-cell malignancies and B-cell-
implicated autoimmune diseases.
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